ASP2998 / Astellas - LARVOL DELTA

ASP2998, a TROP2-targeted immunostimulatory antibody drug conjugate (iADC) with dual payloads, demonstrates potent efficacy and a favorable safety profile in nonclinical models (AACR 2026) - "ASP2998 is a first-in-class dual payload iADC that combines cytotoxic and immuno-stimulatory mechanisms to enhance antitumor efficacy and promote durable antitumor immunity while demonstrating a favorable safety profile in nonhuman primates. A first-in-human (FiH) clinical study is planned."

ADC • Clinical • First-in-human • Oncology • CD4 • CD69 • CD8 • CD80 • GZMB • IFNG • IL1B • IL6 • TACSTD2 • TNFA

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors (clinicaltrials.gov) - P1/2 | N=428 | Recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Breast Cancer • Esophageal Cancer • Gastric Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer • HER-2 • PD-1 • PD-L1 • STING

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors (clinicaltrials.gov) - P1/2 | N=428 | Not yet recruiting | Sponsor: Astellas Pharma Global Development, Inc.

Monotherapy • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer